En el estudio de Beale, presentaron colestasis el 50% de los prematuros 1.500 g 40
Effective management requires individualized dose escalation, patient education, and nonpharmacologic strategies
Glucagon-like peptide-1 receptor agonist (GLP-1RA) and sodium-glucose cotransporter 2 inhibitor (SGLT2i) are currently recommended as first-line hypoglycaemic agents for patients with diabetes with established cardiovascular disease or multiple cardiovascular and renal risks [10]
10.1084/jem.160.1.197 86 WangD.CoutureR.HongY
Besides, GLP-1RAs might be driven by anti-inflammatory mechanisms to inhibit the formation of macrophage foam cells and thus slow down the pathological processes of AS (125, 126)
Structurally, it contains an extracellular N-terminal domain (NTD) and a transmembrane domain (TMD) with -helix bundles (Lei et al., 2018